Artwork

Content provided by Simon Wentworth. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Simon Wentworth or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Breakthroughs in MASH, with 89bio CEO

22:19
 
Share
 

Manage episode 425591889 series 3290640
Content provided by Simon Wentworth. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Simon Wentworth or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH.
It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the USA, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.
One company working in this area is San Francisco-based 89bio (Nasdaq: ETNB), which has a candidate now in Phase III, pegozafermin, and in this episode we are joined by the company’s chief executive, Rohan Palekar.
We are also joined by Dr Arun Sanyal, who is Professor of Medicine at VCU Health and founder of the Liver Trust.

  continue reading

27 episodes

Artwork
iconShare
 
Manage episode 425591889 series 3290640
Content provided by Simon Wentworth. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Simon Wentworth or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH.
It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the USA, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.
One company working in this area is San Francisco-based 89bio (Nasdaq: ETNB), which has a candidate now in Phase III, pegozafermin, and in this episode we are joined by the company’s chief executive, Rohan Palekar.
We are also joined by Dr Arun Sanyal, who is Professor of Medicine at VCU Health and founder of the Liver Trust.

  continue reading

27 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide